This conference call transcript was computer generated and almost certianly contains errors. This transcript is provided for information purposes only.EarningsCall, LLC makes no representation about the accuracy of the aforementioned transcript, and you are cautioned not to place undue reliance on the information provided by the transcript.
5/10/2023
Greetings and welcome to the Matinas Biopharma first quarter 2023 conference call and webcast. At this time, all participants are in listen-only mode. A brief question and answer session will follow the formal presentation. If anyone should require operator assistance during the conference, please press star zero on your telephone keypad. As a reminder, this conference is being recorded. It is now my pleasure to introduce your host, Jody Kane. Thank you, Jody. You may begin.
This is Jody Cain with LHA. Thank you for participating in today's call. Speaking on today's call from Matinas Biopharma will be Jerry DeBoer, Chief Executive Officer, Dr. Terry Makowitz, Chief Development Officer, Dr. Terry Ferguson, Chief Medical Officer, and Keith Kaczynski, Chief Financial Officer. I'd like to remind listeners that remarks made during this call may state management's future intentions hopes, beliefs, expectations, or projections. These are forward-looking statements and involve risks and uncertainties. Forward-looking statements are made pursuant to the safe harbor provisions of the federal securities laws. These forward-looking statements are based on Matinas Biopharma's current expectations and actual results could differ materially. As a result, you should not place undue reliance on any forward-looking statements. Some of the factors that could cause actual results to differ materially from those contemplated by such forward-looking statements are discussed in the periodic reports Bettina's Biopharma files with the Securities and Exchange Commission. These documents are available in the investor section of the company's website and on the SEC's website. Furthermore, the content of this conference call contains information that is accurate only as of the date of the live broadcast, May 10th, 2023. Medina's Biopharma undertakes no obligation to revise or update any statements to reflect events or circumstances, except as required by law. And now I'd like to turn the call over to Jerry Jabbour. Jerry?
Terry, is your line on mute?
You're reading a preview of the MTNB Q1 2023 earnings call.
Free account.
